Phraction Management LLC Grows Position in Danaher Corporation $DHR

Key Points

• Phraction Management LLC increased its stake in Danaher Corporation by 21.3% during the second quarter, bringing its total holdings to 47,182 shares, valued at approximately $9.32 million.
• Danaher reported $1.80 earnings per share (EPS) for the last quarter, exceeding analysts' expectations, with total revenue of $5.94 billion.
• The company will pay a quarterly dividend of $0.32 per share on October 31st, reflecting an annualized yield of 0.6%.

Phraction Management LLC lifted its position in shares of Danaher Corporation (NYSE:DHR - Free Report) by 21.3% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 47,182 shares of the conglomerate's stock after buying an additional 8,280 shares during the period. Danaher makes up about 3.0% of Phraction Management LLC's holdings, making the stock its 11th biggest holding. Phraction Management LLC's holdings in Danaher were worth $9,320,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in shares of Danaher by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate's stock worth $12,296,123,000 after purchasing an additional 230,966 shares during the period. Price T Rowe Associates Inc. MD lifted its position in Danaher by 3.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate's stock valued at $4,016,404,000 after buying an additional 612,154 shares in the last quarter. Bank of New York Mellon Corp grew its stake in Danaher by 2.3% during the first quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate's stock worth $1,800,614,000 after buying an additional 194,466 shares during the period. Invesco Ltd. increased its position in shares of Danaher by 44.5% in the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock worth $965,259,000 after acquiring an additional 1,450,703 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Danaher by 4.0% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 4,230,087 shares of the conglomerate's stock valued at $867,168,000 after acquiring an additional 163,332 shares during the period. Institutional investors and hedge funds own 79.05% of the company's stock.

Danaher Trading Down 1.1%

Shares of NYSE DHR opened at $210.64 on Friday. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. The stock's 50 day moving average price is $200.00 and its two-hundred day moving average price is $197.40. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $279.41. The stock has a market capitalization of $150.83 billion, a P/E ratio of 44.82, a PEG ratio of 3.03 and a beta of 0.77.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The firm had revenue of $5.94 billion for the quarter, compared to analysts' expectations of $5.83 billion. During the same period last year, the business posted $1.72 earnings per share. The firm's revenue for the quarter was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, September 26th. Danaher's dividend payout ratio is currently 27.23%.

Wall Street Analyst Weigh In

DHR has been the topic of several research reports. Scotiabank raised Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price objective on the stock in a research report on Friday, July 11th. Robert W. Baird upped their price target on Danaher from $225.00 to $226.00 and gave the stock an "outperform" rating in a report on Friday, July 18th. Evercore ISI dropped their price objective on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. Royal Bank Of Canada set a $241.00 price target on shares of Danaher in a report on Tuesday, September 2nd. Finally, Barclays reiterated an "overweight" rating and issued a $225.00 price objective (up previously from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Seventeen analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, Danaher presently has an average rating of "Moderate Buy" and a consensus price target of $245.91.

Insiders Place Their Bets

In other news, Director Teri List sold 2,778 shares of the company's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the transaction, the director directly owned 20,751 shares of the company's stock, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 11.10% of the stock is currently owned by company insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.